Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice

Human Molecular Genetics

Volumn 11, Issue 19, 2002, Pages 2233-2241

  Fossale, Elisa ^a   Wheeler, Vanessa C ^a   Vrbanac, Vladimir ^a   Lebel, Lori Anne ^a   Teed, Allison ^a   Mysore, Jayalakshmi S ^a   Gusella, James F ^a   MacDonald, Marcy E ^a   Persichetti, Francesca ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE DERIVATIVE; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; RIBOSOME PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC CODE; GENETIC CONSERVATION; GENETIC SCREENING; HETEROZYGOSITY; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; SYMPTOMATOLOGY;

MURINAE;

EID: 0037106316     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/11.19.2233     Document Type: Article

References (59)

1. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
2. Gusella, J.F. and MacDonald, M.E. (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci., 1, 109-115.
3. Gusella, J. and MacDonald, M. (2002) No post-genetics era in human disease research. Nat. Rev. Genet., 3, 72-79.
4. Myers, R.H., Vonsattel, J.P., Paskevich, P.A., Kiely, D.K., Stevens, T.J., Cupples, L.A., Richardson, E.P., Jr, and Bird, E.D. (1991) Decreased neuronal and increased oligodendroglial densities in Huntington's disease caudate nucleus. J. Neuropathol. Exp. Neurol., 50, 729-742.
5. Furtado, S., Suchowersky, O., Rewcastle, B., Graham, L., Klimek, M.L. and Garber, A. (1996) Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann. Neurol., 39, 132-136.
6. Penney, J.B., Jr., Vonsattel, J.P., MacDonald, M.E., Gusella, J.F. and Myers, R.H. (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol., 41, 689-692.
7. Huang, C.C., Faber, P.W., Persichetti, F., Mittal, V., Vonsattel, J.P., MacDonald, M.E. and Gusella, J.F. (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet., 24, 217-233.
8. Wanker, E.E. (2000) Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol Chem., 381, 937-942.
9. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
10. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
11. Nucifora, F.C., Jr, Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V.L. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science, 291, 2423-2428.
12. Wyttenbach, A., Swartz, J., Kita, H., Thykjaer, T., Carmichael, J., Bradley, J., Brown, R., Maxwell, M., Schapira, A., Orntoft, T.F. et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet., 10, 1829-1845.
13. Li, S.H., Cheng, A.L., Zhou, H., Lam, S., Rao, M., Li, H. and Li, X.J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol., 22, 1277-1287.
14. Li, H., Li, S.H., Johnston, H., Shelbourne, P.F. and Li, X.J. (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet., 25, 385-389.
15. Evert, B.O., Wullner, U. and Klockgether, T. (2000) Cell death in polyglutamine diseases. Cell. Tissue Res., 301, 189-204.
16. MacDonald, M.E. and Wheeler, V.C. (2000) Huntington's disease pathogenesis: Insights from HD mouse models. NeuroScience News, 3, 38-44.
17. Shelbourne, P.F., Killeen, N., Hevner, R.F., Johnston, H.M., Tecott, L., Lewandoski, M., Ennis, M., Ramirez, L., Li, Z., Iannicola, C. et al. (1999) A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum. Mol. Genet., 8, 763-774.
18. Wheeler, V.C., Auerbach, W., White, J.K., Srinidhi. J., Auerbach, A., Ryan, A., Duyao, M.P., Vrbanac, V., Weaver, M., Gusella, J.F. et al. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet., 8, 115-122.
19. Levine, M.S., Klapstein, G.J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M.E., Jokel, E.S., Carpenter, E.M., Zanjani, H., Hurst, R.S. et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-532.
20. Q111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
21. Lin, C.H., Tallaksen-Greene, S., Chien, W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L. and Detloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
22. Wheeler, V.C., Gutekunst, C.A., Vrbanac, V., Lebel, L.A., Schilling, G., Hersch, S., Friedlander, R.M., Gusella, J.F., Vonsattel, J.P., Borchelt, D.R. and MacDonald, M.E. (2002) Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum. Mol. Genet., 11, 633-640.
23. Tsuno, A., Miyoshi, K., Tsujii, R., Miyakawa, T. and Mizuta, K. (2000) RRS1, a conserved essential gene, encodes a novel regulatory protein required for ribosome biogenesis in Saccharomyces cerevisiae. Mol. Cell. Biol., 20, 2066-2074.
24. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P., Jr. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
25. Miyoshi, K., Tsujii, R., Yoshida, H., Maki, Y., Wada, A., Matsui, Y., Toh, E.A. and Mizuta, K. (2002) Normal assembly of 60S ribosomal subunits is required for the signaling in response to a secretory defect in Saccharomyces cerevisiae. J. Biol. Chem., 277, 18334-18339.
26. Tsujii, R., Miyoshi, K., Tsuno, A., Matsui, Y., Toh-e, A., Miyakawa, T. and Mizuta, K. (2000) Ebp2p, yeast homologue of a human protein that interacts with Epstein-Barr virus nuclear antigen 1, is required for pre-rRNA processing and ribosomal subunit assembly. Genes Cells, 5, 543-553.
27. Iqbal, K., Tellez-Nagel, I. and Grundke-Iqbal, I. (1974) Protein abnormalities in Huntington's chorea. Brain Res., 76, 178-184.
28. Hoogeveen, A.T., Willemsen, R., Meyer, N., de Rooij, K.E., Roos, R.A., van Ommen, G.J. and Galjaard, H. (1993) Characterization and localization of the Huntington disease gene product. Hum. Mol. Genet., 2, 2069-2073.
29. De Rooij, K.E., Dorsman, J.C., Smoor, M.A., Den Dunnen, J.T. and Van Ommen, G.J. (1996) Subcellular localization of the Huntington's disease gene product in cell lines by immunofluorescence and biochemical subcellular fractionation. Hum. Mol. Genet., 5, 1093-1099.
30. Wilkinson, F.L., Nguyen, T.M., Manilal, S.B., Thomas, P., Neal, J.W., Harper, P.S., Jones, A.L. and Morris, G.E. (1999) Localization of rabbit huntingtin using a new panel of monoclonal antibodies. Brain Res. Mol. Brain Res., 69, 10-20.
31. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and MacDonald, M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
32. Kegel, K.B., Meloni, A.R., Yi, Y., Kim, Y.J., Doyle, E., Cuiffo, B.G., Sapp, E., Wang, Y., Qin, Z.H., Chen, J.D. et al. (2000) Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem., 277, 7466-7476.
33. Hilditch-Maguire, P., Trettel, F., Passani, L.A., Auerbach, A., Persichetti, F. and MacDonald, M.E. (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet., 9, 2789-2797.
34. Faber, P.W., Barnes, G.T., Srinidhi, J., Chen, J., Gusella, J.F. and MacDonald, M.E. (1998) Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet., 7, 1463-1474.
35. Boutell, J.M., Thomas, P., Neal, J.W., Weston, V.J., Duce, J., Harper, P.S. and Jones, A.L. (1999) Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet., 8, 1647-1655.
36. Rega, S., Stiewe, T., Chang, D.I., Pollmeier, B., Esche, H., Bardenheuer, W., Marquitan, G. and Putzer, B.M. (2001) Identification of the full-length huntingtin-interacting protein p231HBP/HYPB as a DNA-binding factor. Mol. Cell. Neurosci., 18, 68-79.
37. McCampbell, A., Taylor, J.P., Taye, A.A. Robitschek, J., Li, M., Walcott, J., Merry, D., Chai, Y., Paulson, H., Sobue, G. and Fischbeck, K.H. (2000) CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet., 9, 2197-2202.
38. Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet., 26, 300-306.
39. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science, 293, 493-498.
40. Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F. and Sipione, S. (2001) Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci., 24, 182-188.
41. Leavitt, B.R., Guttman, J.A., Hodgson, J.G., Kimel, G.H., Singaraja, R., Vogl, A.W. and Hayden, M.R. (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am. J. Hum. Genet., 68, 313-324.
42. Song, C., Perides, G. and Liu, Y.F. (2002) Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J. Biol. Chem., 277, 6703-6707.
43. Cha, J.H., Frey, A.S., Alsdorf, S.A., Kerner, J.A., Kosinski, C.M., Mangiarini, L., Penney, J.B., Jr, Davies, S.W., Bates, G.P. and Young, A.B. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil. Trans. R. Soc. Lond. B Biol. Sci., 354, 981-989.
44. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J. Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
45. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
46. Wellington, C.L., Singaraja, R., Ellerby, L., Savill, J., Roy, S., Leavitt, B., Cattaneo, E., Hackam, A., Sharp, A., Thornberry, N. et al. (2000) Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem., 275, 19831-19838.
47. Ona, V.O., Li, M., Vonsattel, J.P., Andrews, L.J., Khan, S.Q., Chung, W.M., Frey, A.S., Menon, A.S., Li, X.J., Stieg, P.E. et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 399, 263-267.
48. Rigamonti, D., Sipione, S., Goffredo, D., Zuccato, C., Fossale, E. and Cattaneo, E. (2001) Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J. Biol. Chem., 276, 14545-14548.
49. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt. Dev. Cell, 2, 831-837.
50. Lin, X., Antalffy, B., Kang, D., Orr, H.T. and Zoghbi, H.Y. (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1, Nat. Neurosci., 3, 157-163.
51. Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M., Yunis, W.S., Duvick, L.A., Zoghbi, H.Y. and Orr, H.T. (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell, 82, 937-948.
52. Watase, K., Weeber, E.J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D.L. et al. (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34, 905-919.
53. Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S. and Kakizuka, A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet., 13, 196-202.
54. Garden, G.A., Libby, R.T., Fu, Y.H., Kinoshita, Y., Huang, J., Possin, D.E. Smith, A.C., Martinez, R.A., Fine, G.C., Grote, S.K. et al. (2002) Polyglutamine-expanded ataxin-7 promotes non-cell-autonomous purkinje cell degeneration and displays proteolytic cleavage in ataxic transgenic mice. J. Neurosci., 22, 4897-4905.
55. Schilling, G., Wood, J.D., Duan, K., Slunt, H.H., Gonzalez, V., Yamada, M., Cooper, J.K., Margolis, R.L., Jenkins, N.A., Copeland, N.G. et al. (1999) Nuclear accumulation of truncated atrophin 1 fragments in a transgenic mouse model of DRPLA. Neuron, 24, 275-286.
56. Bingham, P.M., Scott, M.O., Wang, S., McPhaul, M.J., Wilson, E.M., Garbern, J.Y., Merry, D.E. and Fischbeck, K.H. (1995) Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mic. Nat. Genet., 9, 191-196.
57. La Spada, A.R., Peterson, K.R., Meadows, S.A., McClain, M.E., Jeng, G., Chmelar, R.S., Haugen, H.A., Chen, K., Singer, M.J., Moore, D. et al. (1998) Androgen receptor YAC transgenic mice carrying CAG 45 alleles show trinucleotide repeat instability. Hum. Mol. Genet., 7, 959-967.
58. White, J.K., Auerbach, W., Duyao, M.P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L. and MacDonald, M.E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet., 17, 404-410.
59. Warner, J.P., Barron, L.H. and Brock, D.J. (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol. Cell. Probes, 7, 235-239.